Source comparison
Tesamorelin + Ipamorelin Blend Research Review: Efficacy vs Monotherapy Comparison
The table below summarizes key differences between tesamorelin monotherapy, ipamorelin monotherapy, and the tesamorelin + ipamorelin blend based on available research data and controlled study outcomes. | Protocol | Mechanism | Mean IGF-1 Increase (ng/mL at 12
This comparison does not assign a generated winner or score.
- The table below summarizes key differences between tesamorelin monotherapy, ipamorelin monotherapy, and the tesamorelin + ipamorelin blend based on available research data and controlled study outcomes.
- | Protocol | Mechanism | Mean IGF-1 Increase (ng/mL at 12 weeks) | Peak GH Response (ng/mL) | Receptor Desensitization Risk | Adverse Event Profile | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin 2mg daily | GHRH receptor agonist. Stimulates anterior pituitary GH synthesis and release | 80–100 | 6–10 (30–60 min post-dose) | Moderate. Continuous dosing may reduce GHRH receptor expression after 8–12 weeks | Mild injection site reactions (10–15%), transient edema (5–8%) | Proven efficacy for VAT reduction and IGF-1 elevation; FDA-approved for lipodystrophy; risk of receptor downregulation with continuous use || Ipamorelin 200mcg twice daily | Selective ghrelin receptor (GHS-R1a) agonist. Triggers GH secretion via calcium-dependent pathway | 40–70 | 8–12 (30–45 min post-dose) | Low. Selectivity and pulsatile dosing minimize tachyphylaxis | Minimal; no cortisol or prolactin elevation; rare mild water retention | Clean GH pulse without off-target hormone effects; lower IGF-1 elevation